Fredrik O L Nilsson (Fredrik Nilsson)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Clinical Practice

Cross Sectional

Top Venues

Future oncology (London, England)

Acta oncologica (Stockholm, Sweden)

Applied health economics and health policy

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Jakobsson, Angela Strambi, Fredrik O L Nilsson, Johannes Arpegård, Johan Dalén
Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population. Future oncology (London, England) (2024)
Jaesh Naik, Norma Beavers, Fredrik O L Nilsson, Laura Iadeluca, Chrissy Lowry
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden. Applied health economics and health policy (2023)
Rosa Lauppe, Fredrik O L Nilsson, Hanna Fues Wahl, Mathias Lilja, Anders Vikström, Sandra T Asanin
Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study. Acta oncologica (Stockholm, Sweden) 61 (11) (2022)
Fredrik O L Nilsson, Sandra T Asanin, Elizabeth T Masters, Laura Iadeluca, Chrissy Almond, Miranda Cooper, Sarah Smith
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden. PharmacoEconomics 39 (8) (2021)